A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).

Completed

Conditions studied: ATTR-CM

In brief

This is an observational, retrospective non-inferiority study with a study sample from a large national database. A machine learning (ML) model will use a national database to predict the clinical diagnosis of ATTRwt-CM among HF patients. This study will include HF patients ≥50 years old.

Key facts

Study ID

NCT06029452

Run by

Pfizer

People needed

558

Starts

2023-09-01

Expected to finish

2023-11-14

Last updated by the study team

2025-01-03

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HF patients (defined as having ≥1 claim for HF or HF treatment) ≥50 years old with clinical diagnosis of ATTRwt-CM or non-amyloid HF ascertained by charts. Patients will be required to have ≥12 months of continuous activity in the EHR or claims prior to the Index Date.

You may not qualify if…

• Patients with any of the following diagnoses:
• Light chain (AL) amyloidosis
• Intracranial hemorrhage
• Cerebral amyloid angiopathy
• End stage renal disease
• Blood cancer

Where it is running

• Pfizer — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.